ELISPOT检测HLA-A*0201转基因小鼠对恶性疟原虫红前期候选抗原的CTL应答  

CTL Response to Pre-erythrocytic Stage Vaccine Candidate of Plasmodium falciparum in HLA-A*0201 Transgenic Mice Detected by ELISPOT Assay

作　　者：钱锋[1] 张青锋[1] 沈璐辉[1] 潘卫庆[1] 

机构地区：[1]第二军医大学病原生物学教研室,上海200433

出　　处：《中国寄生虫学与寄生虫病杂志》2006年第4期319-320,F0003,共3页Chinese Journal of Parasitology and Parasitic Diseases

基　　金：世界卫生组织热带病研究和培训计划项目(No.A20198)~~

摘　　要：用恶性疟原虫红前期多表位候选抗原PfCP-3tcl(含有1个HLAA*0201限制的CTL表位YLNKIQNSL)免疫人白细胞抗原复合体(HLA)A*0201(HLA-A*0201)转基因小鼠,再用鼠γ干扰素(IFN-γ)酶联免疫吸附斑点法(ELISPOT)检测该转基因小鼠特异性CTL应答,尝试在转基因实验动物中建立评价恶性疟原虫红前期候选抗原CTL应答的方法。结果显示该候选抗原中含有的CTL表位在转基因小鼠体内激发出了特异性的CTL应答,表明该CTL表位在转基因小鼠体内能够正确地加工和递呈。The importance of cytotoxic T-lymphocyte （CTL） against malaria parasite in pre-erythrocytic stage has been presented in relevant researches. In order to investigate whether one CTL epitope （YLNKIQNSL） involved in a chimeric pre-erythrocytic stage vaccine candidate of Plasmodium falciparum which was expressed and purified in the laboratory can stimulate in vivo CTL response, HLA-A＊0201 transgenic mice were immunized with this vaccine candidate. Enzyme-linked immunosorbent spot （ELISPOT） assay was performed on the splenocytes from the immunized transgenic mice. Positive result indicated that this CTL epitope can be in vivo processed and correctly presented.

关 键 词：疫苗 恶性疟 红细胞前期 细胞毒T淋巴细胞 ELISPOT检测 

分 类 号：R382.312[医药卫生—医学寄生虫学] R392.11[医药卫生—基础医学]